A 58-year-old Black man with hypertension and diabetes mellitus presents with a growing, solitary nodule on his lower back that has been present for the past year. A 58-year-old Black man with ...

The widespread utilization of chest CT scans has increased the importance of the proper evaluation of incidentally found lung nodules. The primary goal in the evaluation of these nodules is to ...

Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...

Gilead has several patent applications in India on lenacapavir. Two of these patent applications, filed in 2020, seek patents on the choline and sodium salt of the drug lenacapavir. The Indian ...

The Indian Patent Office is set to hear the objections against the grant of patent claims filed by U.S.-based pharmaceutical company Gilead Sciences on the HIV drug Lenacapavir later this week.

Felix Mogaka, a clinical scientist at Kenya Medical Research Institute (KEMRI), says lenacapavir treatment, an investigational drug to prevent HIV infection, presents effective outcomes given ...

Patient and public health groups worry about a potential patent grant to Gilead Sciences for the HIV drug lenacapavir in India, which could hinder affordable generic production. The Indian Patent ...

The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case scheduled to come up this week at the Indian Patent Office (IPO).

“Daina Graybosch has given his Hold rating due to a combination of factors surrounding Gilead Sciences’ prospects with its new drug, lenacapavir.” Daina Graybosch’s assessment of Gilead ...

Chris Schott has given his Buy rating due to a combination of factors revolving around Gilead Sciences’ drug, lenacapavir, and its potential impact on the market. Schott points out the ...